Literature DB >> 20179682

Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons.

Matthew R J Mason1, Erich M E Ehlert, Ruben Eggers, Chris W Pool, Stephan Hermening, Angelina Huseinovic, Eric Timmermans, Bas Blits, Joost Verhaagen.   

Abstract

For many experiments in the study of the peripheral nervous system, it would be useful to genetically manipulate primary sensory neurons. We have compared vectors based on adeno-associated virus (AAV) serotypes 1, 2, 3, 4, 5, 6, and 8, and lentivirus (LV), all expressing green fluorescent protein (GFP), for efficiency of transduction of sensory neurons, expression level, cellular tropism, and persistence of transgene expression following direct injection into the dorsal root ganglia (DRG), using histological quantification and qPCR. Two weeks after injection, AAV1, AAV5, and AAV6 had transduced the most neurons. The time course of GFP expression from these three vectors was studied from 1 to 12 weeks after injection. AAV5 was the most effective serotype overall, followed by AAV1. Both these serotypes showed increasing neuronal transduction rates at later time points, with some injections of AAV5 yielding over 90% of DRG neurons GFP(+) at 12 weeks. AAV6 performed well initially, but transduction rates declined dramatically between 4 and 12 weeks. AAV1 and AAV5 both transduced large-diameter neurons, IB4(+) neurons, and CGRP(+) neurons. In conclusion, AAV5 is a highly effective gene therapy vector for primary sensory neurons following direct injection into the DRG.

Entities:  

Mesh:

Year:  2010        PMID: 20179682      PMCID: PMC2862541          DOI: 10.1038/mt.2010.19

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  47 in total

1.  Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors.

Authors:  Sergei Zolotukhin; Mark Potter; Irene Zolotukhin; Yoshihisa Sakai; Scott Loiler; Thomas J Fraites; Vince A Chiodo; Tina Phillipsberg; Nicholas Muzyczka; William W Hauswirth; Terance R Flotte; Barry J Byrne; Richard O Snyder
Journal:  Methods       Date:  2002-10       Impact factor: 3.608

Review 2.  Exploiting the neurotherapeutic potential of peptides: targeted delivery using HSV vectors.

Authors:  Joseph C Glorioso; Marina Mata; David J Fink
Journal:  Expert Opin Biol Ther       Date:  2003-12       Impact factor: 4.388

3.  Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain.

Authors:  C Wang; C-M Wang; K R Clark; T J Sferra
Journal:  Gene Ther       Date:  2003-08       Impact factor: 5.250

Review 4.  Adeno-associated viral vectors as agents for gene delivery: application in disorders and trauma of the central nervous system.

Authors:  Marc J Ruitenberg; Ruben Eggers; Gerard J Boer; Joost Verhaagen
Journal:  Methods       Date:  2002-10       Impact factor: 3.608

5.  Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system.

Authors:  Corinna Burger; Oleg S Gorbatyuk; Margaret J Velardo; Carmen S Peden; Philip Williams; Sergei Zolotukhin; Paul J Reier; Ronald J Mandel; Nicholas Muzyczka
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

6.  Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats.

Authors:  Jean-Charles Paterna; Joram Feldon; Hansruedi Büeler
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

7.  Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6.

Authors:  Dirk Grimm; Mark A Kay; Juergen A Kleinschmidt
Journal:  Mol Ther       Date:  2003-06       Impact factor: 11.454

8.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain.

Authors:  M G Kaplitt; P Leone; R J Samulski; X Xiao; D W Pfaff; K L O'Malley; M J During
Journal:  Nat Genet       Date:  1994-10       Impact factor: 38.330

9.  Efficiencies of transgene expression in nociceptive neurons through different routes of delivery of adeno-associated viral vectors.

Authors:  Ya Xu; Yanping Gu; Ping Wu; Guang-Wen Li; Li-Yen Mae Huang
Journal:  Hum Gene Ther       Date:  2003-06-10       Impact factor: 5.695

10.  Efficient delivery of Cre-recombinase to neurons in vivo and stable transduction of neurons using adeno-associated and lentiviral vectors.

Authors:  Bushra Y Ahmed; Sridhara Chakravarthy; Ruben Eggers; Wim T J M C Hermens; Jing Ying Zhang; Simone P Niclou; Christiaan Levelt; Fred Sablitzky; Patrick N Anderson; A R Lieberman; Joost Verhaagen
Journal:  BMC Neurosci       Date:  2004-01-30       Impact factor: 3.288

View more
  84 in total

1.  AAV provides an alternative for gene therapy of the peripheral sensory nervous system.

Authors:  Andreas S Beutler
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

Review 2.  Gene therapy approaches to enhancing plasticity and regeneration after spinal cord injury.

Authors:  Steffen Franz; Norbert Weidner; Armin Blesch
Journal:  Exp Neurol       Date:  2011-01-31       Impact factor: 5.330

3.  Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed.

Authors:  David B Wang; Robert D Dayton; Phillip P Henning; Cooper D Cain; Li Ru Zhao; Lisa M Schrott; Elysse A Orchard; David S Knight; Ronald L Klein
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

4.  Amygdalar expression of the microRNA miR-101a and its target Ezh2 contribute to rodent anxiety-like behaviour.

Authors:  Joshua L Cohen; Nateka L Jackson; Mary E Ballestas; William M Webb; Farah D Lubin; Sarah M Clinton
Journal:  Eur J Neurosci       Date:  2017-07-06       Impact factor: 3.386

5.  Gene delivery to rat and human Schwann cells and nerve segments: a comparison of AAV 1-9 and lentiviral vectors.

Authors:  S A Hoyng; F De Winter; S Gnavi; L van Egmond; C L Attwell; M R Tannemaat; J Verhaagen; M J A Malessy
Journal:  Gene Ther       Date:  2015-05-04       Impact factor: 5.250

6.  Dorsal Root Ganglion Injection and Dorsal Root Crush Injury as a Model for Sensory Axon Regeneration.

Authors:  Menghon Cheah; James W Fawcett; Melissa R Andrews
Journal:  J Vis Exp       Date:  2017-05-03       Impact factor: 1.355

7.  Adeno-associated virus-2-mediated TGF-β1 microRNA transfection inhibits adhesion formation after digital flexor tendon injury.

Authors:  Y F Wu; W F Mao; Y L Zhou; X T Wang; P Y Liu; J B Tang
Journal:  Gene Ther       Date:  2015-10-08       Impact factor: 5.250

8.  Visualization of spinal afferent innervation in the mouse colon by AAV8-mediated GFP expression.

Authors:  D J Schuster; J A Dykstra; M S Riedl; K F Kitto; C N Honda; R S McIvor; C A Fairbanks; L Vulchanova
Journal:  Neurogastroenterol Motil       Date:  2012-12-18       Impact factor: 3.598

9.  AAV-Mediated Gene Transfer to Dorsal Root Ganglion.

Authors:  Hongwei Yu; Gregory Fischer; Quinn H Hogan
Journal:  Methods Mol Biol       Date:  2016

10.  Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system.

Authors:  Erich M Ehlert; Ruben Eggers; Simone P Niclou; Joost Verhaagen
Journal:  BMC Neurosci       Date:  2010-02-18       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.